Zurück zu Projekte

15236.1 PFLS-LS

Development of a new Gastro-Retentive Drug Delivery Technology: In Vitro and In Vivo validation studies using MRI

Zusammenfassung

Development of a new Gastro-Retentive Drug Delivery Technology: In Vitro and In Vivo validation studies using MRI

Weitere Texte

Abstract

There is an increasing trend in the pharmaceutical industry to develop products based on new oral drug delivery technologies. This is mainly driven by the fact that delivery and establishment of a sufficient and controllable bioavailability of drugs are the major challenges of current oral dosage formulation developments. Innovative and new oral delivery techniques are not only of great interest for new products based on new chemical entities (NCE), but are also required to improve the efficacy of existing products.|In the context of these pharmaceutical challenges the proposed project aims at the development and validation of a patent protected pharmaceutical drug delivery formulation based on a new gastro-retentive technology platform. This granules based new gastro-retentive formulation technology will exhibit increased gastric retention, i.e. longer intra-gastric residence times, as compared to standard oral formulations. It is formed by the binding of active pharmaceutical ingredients (APIs) within a floating polymer matrix. The developed oral dosage technology will provide targeted and controlled delivery of therapeutic agents into the upper GI tract, the most effective site of absorption for many oral drug substances.|

Beteiligte

Till Röhrich

Wirtschaftspartner

till.roehrich@siegfried.ch

Siegfried Ltd. Till Röhrich Untere Brühlstrasse 4 4800 Zofingen AG CH

Andreas Steingötter

Kontaktperson

steingoetter@biomed.ee.ethz.ch

USZ Universitätsspital Zürich Division of Gastroenterology and He Andreas Steingötter Rämistrasse 100 8091 Zürich ZH CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2013-07-31
Enddatum
2016-05-31
Bewilligte Gesamtkosten
CHF 277710.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • T490 Biotechnology 100.0%